Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 22210658.
- Also identified by DOI 10.1093/rheumatology/ker404.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL). A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36-52 weeks with ETN 50 mg s.c. once weekly. Analysis included direct costs (transformed out-patient and in-patient care elements), indirect costs (sick leave and lost working days), efficacy and QoL. Annualized direct and indirect costs decreased (55.5%, P ≤ 0.008) during ETN treatment, as did out-patient and in-patient episodes (physiotherapist/physician visits, P = 0.012). Work productivity and QoL increased. ETN therapy significantly reduces direct and indirect health-care costs and increases work ability and QoL in AS. Trial Registration. EUDRACT, https://eudract.ema.europa.eu/, 2006-001061-42.
Medical subject headings
- Antirheumatic Agents
- Health Care Costs
- Immunoglobulin G
- Quality of Life
- Receptors, Tumor Necrosis Factor
- Spondylitis, Ankylosing